DOCSLIB.ORG

Supplementary Tables 4 and 5-Cleany

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Tables 4 and 5-Cleany Supplementary material J Med Genet Supplementary Table 4: Summary of inconclusive cancer cases ID Test indication Sex Age Gene; transcript Variant (cDNA, Zygosity Relatives ACMG OMIM phenotypes protein) class #T #P 003 Colorectal cancer F 48 APC c.3920T>A, Het 1 (a) 0 VUS Adenoma, periampullary, somatic; Adenomatous (NM_000038.5) (p.Ile1307Lys) polyposis coli (AD); Brain tumor-polyposis (AD) syndrome 2; Colorectal cancer, somatic; Desmoid disease, hereditary (AD); Gardner syndrome (AD); Gastric cancer, somatic; Hepatoblastoma, somatic 005 Lymphoma; mixed F 57 APC c.6724A>G, Het 1 (a) 0 VUS Adenoma, periampullary, somatic; Adenomatous polyposis; colorectal (NM_000038.5) (p.Ser2242Gly) polyposis coli (AD); Brain tumor-polyposis (AD) cancer syndrome 2; Colorectal cancer, somatic; Desmoid disease, hereditary (AD); Gardner syndrome (AD); Gastric cancer, somatic; Hepatoblastoma, somatic 008 Cholangiocarcinoma F 29 APC c.620G>A, Het 1 (a) 1 VUS Adenoma, periampullary, somatic; Adenomatous (NM_000038.5) (p.Cys207Tyr) polyposis coli (AD);Brain tumor-polyposis (AD) syndrome 2; Colorectal cancer, somatic; Desmoid disease, hereditary (AD); Gardner syndrome (AD);Gastric cancer, somatic; Hepatoblastoma, somatic 009 Colorectal cancer; M 75 BMPR1A c.729C>G, Het 1 (a) 0 VUS Juvenile polyposis syndrome, infantile form (AD); ameliogensis (NM_004329); (p.Gly243Gly) Hereditary mixed polyposis syndrome; Juvenile intestinal imperfecta polyposis (AD) MSH6 c.1273A>G, Het VUS Hereditary nonpolyposis colorectal cancer, type 5 (AD); (NM_000179) (p.Ile425Val) mismatch repair cancer syndrome 010 Colorectal cancer; F 53 MSH3 c.1992G>A Het 1(a) 1 VUS Endometrial carcinoma, somatic; familial adenomatous melanoma (NM_002439.4) (p.Gln664=) polyposis 4 011 Polyposis (40 F 68 POLD1 c.2570C>T, Het - - VUS Mandibular hypoplasia, deafness, progeroid features, and polyps); (NM_001308632) (p.Ala857Val) lipodystrophy syndrome (AD); Susceptibility to colon cancer type 10 (AD) 018 Ocular lymphoma; F 65 PTEN c.810G>T, Het - - VUS Cowden syndrome 1 (AD); Lhermitte-Duclos syndrome pancreatic cancer; (NM_000314) (p.Met270Ile) (AD); Macrocephaly/autism syndrome (AD); Prostate breast cancer cancer, somatic; Glioma susceptibility 2; Meningioma (AD) 020 Breast cancer F 54 PMS2 c.727G>T, Het - - VUS Hereditary nonpolyposis colorectal cancer type 4; (NM_000535) (p.Val243Phe) Mismatch repair cancer syndrome (AR) Shickh S, et al. J Med Genet 2020;0:1–9. doi: 10.1136/jmedgenet-2020-106936 Supplementary material J Med Genet Supplementary Table 5: Summary of inconclusive non-cancer cases Variant (cDNA, Relatives ACMG ID Test indication Sex Age Gene; transcript Zygosity OMIM phenotypes protein) #T #P class 016 Bilateral ectopia F 64 LTBP2 c.2541A>G, Het - - VUS Recessive Weill-Marchesani syndrome type 3 (AR); lentis NM_000428) (p.Arg847Arg) Primary congenital glaucoma 3D; Microspherophakia c.4964A>G, Het VUS and/or megalocornea, with ectopia lentis and with or (p.Tyr1655Cys) without secondary glaucoma (AR) 019 Achalasia, HL, F 20 CHD7 (NM_017780) c.2123G>A, Het 2 (u) 1 VUS CHARGE syndrome (AD); hypogonadotrophic corneal/ retinal (p.Ser708Asn) hypogonadism 5 with or without anosmia (AD) anomalies, c.7246G>C, 1 VUS delayed (p.Arg2449Thr) growth/puberty, RECQL4 c.520C>T, 1 VUS gastric (NM_004260) (p.His174Tyr) Baller-Gerold syndrome (AR); RAPADILINO syndrome dysmotility, c.3190C>T, 1 VUS (AR); Rothmund-Thomson syndrome (AR) dysmorphism (p.Arg1064Cys) 025 Duodenal F 50 NTHL1 c.527T>C, Het - - VUS Familial adenomatous polyposis 3 (AR) adenomas; IBS; (NM_002528) (p.Ile176Thr) GERD SEC23B c.1512T>C, Cowden syndrome 7 (AD); Dyserythropoietic anemia, (NM_001172745) (p.Asn504Asn) congenital, type 2 (AR) 026 Bilateral renal F 61 NEK8(NM_178170) c.450C>G, Het 4 (a) 4 VUS Nephronophthisis 9; Renal-hepatic-pancreatic dysplasia 2 cysts (p.Ile150Met) (AR) 027 Cerebellar ataxia, M 73 SUMF1 c.463T>C, Het 1 (a) 1 P Multiple sulfatase deficiency (AR) neuropathy (NM_001164675) (p.Ser155Pro) COL12A1 c.2956T>C Het VUS Ullrich congenital muscular dystrophy; Bethlem myopathy (NM_080645.2) (P.Tyr986His) 2 (AD) GAA(NM_000152.5) c.-32-13T>G Het P Glyogen Storage Disease Type II (Pompe) (AR) 028 Atrial septal M 27 PKD1 c.8293C>T, Het 3 (a) 3 LP† Polycystic kidney disease 1 (AD) defect; Aortic (NM_000296) (p.Arg2765Cys) † dilatation 032 Thin skin, unusual M 61 ABCC6 c.3823C>T, Het - - P Arterial calcification, generalized, of infancy type 2 (AR); scarring, absent (NM_001171) (p.Arg1275X) Pseudoxanthoma elasticum (AR); Pseudoxanthoma subcutaneous elasticum, forme fruste (AD) Shickh S, et al. J Med Genet 2020;0:1–9. doi: 10.1136/jmedgenet-2020-106936 Supplementary material J Med Genet tissue, bleeding disorder 033 Type A ascending M 76 NOTCH1 c.2734C>T, Het 1 (a) 1 VUS Adams-Oliver syndrome type 5 (AD); Aortic valve disease aortic dissection (NM_017617) (p.Arg912Trp) type 1 (AD) PKD2 c.484C>T, Het VUS Polycystic kidney disease 2 (AD) (NM_000297) (p.Pro162Ser) 035 Seizures; F 40 DHTKD1 c.2185G>A, Het 2 (u) 1 LP 2-aminoadipic 2-oxoadipic aciduria (AR); Charcot- dysmorphism; (NM_018706) (p.Gly729Arg) Marie-Tooth disease, axonal, type 2Q (AD) congenital microcephaly; severe ID; clubbed feet; hypertonia 058 Recurrent F 29 ATP2A1 c.733 G>A, Het - - VUS Brody myopathy (AR) rhabdomyolosis; (NM_173201.3) (p.Asp245Asn) cardiac CTDP1 c.227 C>A, (p. Het VUS Congenital cataracts, facial dysmorphism, and dysfunction (NM_004715.4) Pro76His) neuropathy (AR) 059 Memory loss, F 66 GALC c.334A>G Het - - P Krabbe disease (AR) seizures (P); (NM_000253.3) p.Thr96Ala white matter lesions 060 Progressive F 38 SYNE1 c.8003 A>G, Het 2 (u) 1 VUS Emery-Dreifuss muscular (AD); asymmetric (NM_1896.2) (p.Gln2668Arg) Spinocerebellar ataxia 8 (AR) muscle atrophy with weakness 068 Moyamoya F 38 LIPE c.3212delG Het - - LP Familial partial lipodystrophy type 6 (AR) vasculopathy; (NM_005357) (p.Gly1071fs) Cushing’s c.1252 G>A Het VUS disease; recurrent (p.Ala418Thr) kidney stones; MEGF8 c. 7409_7414del Het VUS Carpenter syndrome type 2 (AR) unilateral (NM_001410) (p.2470_2472del) postaxial Shickh S, et al. J Med Genet 2020;0:1–9. doi: 10.1136/jmedgenet-2020-106936 Supplementary material J Med Genet polydactyly; c.4233C>T Het VUS polycythemia; (p.Pro1411Pro) proptic eyes; partial bilateral RNF213 c.2745 A>C Het VUS Susceptibility to Moyamoya disease type 2 2,3 syndactyly (NM_001256071) (p.Arg915Arg) EVC2 c.3241T>G Het VUS Ellis-van Creveld syndrome (AR); Weyers acrofacial (NM_001166136) (p.Ser1081Ala) dysostosis (AD) 072 Mast cell F 42 CYBA c.467delC, Het - - LP Chronic granulomatous disease, autosomal, due to activation; (NM_000101.3) (p.Pro156Argfs*35) deficiency of CYBA (AR) postural IRF3 c.391G>A, Het VUS Susceptibility to acute, infection-induced (herpes-specific) orthostatic (NM_001197126.1) (p.Ala131Thr) encephalopathy type 7 AD) tachycardia syndrome OTULIN c.61C>A, Het VUS Autoinflammation, panniculitis, and dermatosis syndrome (NM_138348) (p.Pro21Thr) (AR) PDE4D c.79A>T, Het VUS Acrodysostosis 2, with or without hormone resistance (NM_001104631) (p.Lys27X) (AD); PEPD c.823delG, Het LP Prolidase deficiency (AR) (NM_001166056) (p.Val275fs) TPSAB1 c.422_423delinsTG, Het VUS Irritable bowel syndrome, cutaneous complaints, (NM_003294) (p.Thr141Met) connective tissue abnormalities, and dysautonomia (AD) TRPM4 c.1459_1495del, Het VUS Progressive familial heart block, type IB (AD) (NM_017636.3) (p.Arg499Glnfs*16) 074 Connective tissue M 60 ANK2 c.10339_10341del Het - - VUS Cardiac arrhythmia, ankyrin-B-related (AD); Long QT disorder NYD; (NM_001148) (p.3447_3447del) syndrome 4 (AD) aortic root KRAS (NM_033360) c.470A>G Het VUS Arteriovenous malformation of the brain, somatic; Bladder dilation (p.Tyr157Cys) cancer, somatic; Breast cancer, somatic Cardiofaciocutaneous syndrome 2; Gastric cancer, somatic; Leukemia, acute myeloid (AD, Smu); Lung cancer, somatic; Noonan syndrome type 3 (AD); Pancreatic carcinoma, somatic; RAS-associated autoimmune leukoproliferative disorder (AD); Shickh S, et al. J Med Genet 2020;0:1–9. doi: 10.1136/jmedgenet-2020-106936 Supplementary material J Med Genet Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic SPECC1L c.3310 G>A Het VUS Facial clefting (AD), oblique; Hypertelorism, Teebi type (NM_015330) (p.Val1104Met) (AD); Opitz GBBB syndrome, type II (AD) 077 Premenopausal F 38 GALNS c.1127G>A Het - - VUS Mucopolysaccharidosis IVA (AR) osteoporosis with (NM_001323544) (p.Arg376Gln) compression fractures; pulmonary issues; severe progressive scoliosis; AVM; unilateral hearing loss †hypomorphic allele Abbreviations: a=affected, u=unaffected, T =tested, P=positive Shickh S, et al. J Med Genet 2020;0:1–9. doi: 10.1136/jmedgenet-2020-106936.
Load more

Recommended publications
  • List of Genes Associated with Sudden Cardiac Death (Scdgseta) Gene
    List of genes associated with sudden cardiac death (SCDgseta) mRNA expression in normal human heart Entrez_I Gene symbol Gene name Uniprot ID Uniprot name fromb D GTEx BioGPS SAGE c d e ATP-binding cassette subfamily B ABCB1 P08183 MDR1_HUMAN 5243 √ √ member 1 ATP-binding cassette subfamily C ABCC9 O60706 ABCC9_HUMAN 10060 √ √ member 9 ACE Angiotensin I–converting enzyme P12821 ACE_HUMAN 1636 √ √ ACE2 Angiotensin I–converting enzyme 2 Q9BYF1 ACE2_HUMAN 59272 √ √ Acetylcholinesterase (Cartwright ACHE P22303 ACES_HUMAN 43 √ √ blood group) ACTC1 Actin, alpha, cardiac muscle 1 P68032 ACTC_HUMAN 70 √ √ ACTN2 Actinin alpha 2 P35609 ACTN2_HUMAN 88 √ √ √ ACTN4 Actinin alpha 4 O43707 ACTN4_HUMAN 81 √ √ √ ADRA2B Adrenoceptor alpha 2B P18089 ADA2B_HUMAN 151 √ √ AGT Angiotensinogen P01019 ANGT_HUMAN 183 √ √ √ AGTR1 Angiotensin II receptor type 1 P30556 AGTR1_HUMAN 185 √ √ AGTR2 Angiotensin II receptor type 2 P50052 AGTR2_HUMAN 186 √ √ AKAP9 A-kinase anchoring protein 9 Q99996 AKAP9_HUMAN 10142 √ √ √ ANK2/ANKB/ANKYRI Ankyrin 2 Q01484 ANK2_HUMAN 287 √ √ √ N B ANKRD1 Ankyrin repeat domain 1 Q15327 ANKR1_HUMAN 27063 √ √ √ ANKRD9 Ankyrin repeat domain 9 Q96BM1 ANKR9_HUMAN 122416 √ √ ARHGAP24 Rho GTPase–activating protein 24 Q8N264 RHG24_HUMAN 83478 √ √ ATPase Na+/K+–transporting ATP1B1 P05026 AT1B1_HUMAN 481 √ √ √ subunit beta 1 ATPase sarcoplasmic/endoplasmic ATP2A2 P16615 AT2A2_HUMAN 488 √ √ √ reticulum Ca2+ transporting 2 AZIN1 Antizyme inhibitor 1 O14977 AZIN1_HUMAN 51582 √ √ √ UDP-GlcNAc: betaGal B3GNT7 beta-1,3-N-acetylglucosaminyltransfe Q8NFL0
    [Show full text]
  • Heterotrimeric Go Protein Links Wnt-Frizzled Signaling with Ankyrins to Regulate the Neuronal Microtubule Cytoskeleton Anne-Marie Lüchtenborg1,2, Gonzalo P
    © 2014. Published by The Company of Biologists Ltd | Development (2014) 141, 3399-3409 doi:10.1242/dev.106773 RESEARCH ARTICLE Heterotrimeric Go protein links Wnt-Frizzled signaling with ankyrins to regulate the neuronal microtubule cytoskeleton Anne-Marie Lüchtenborg1,2, Gonzalo P. Solis1, Diane Egger-Adam2, Alexey Koval1, Chen Lin1,2, Maxime G. Blanchard1, Stephan Kellenberger1 and Vladimir L. Katanaev1,2,* ABSTRACT The evolutionarily conserved Wg pathway is important for Drosophila neuromuscular junctions (NMJs) represent a powerful numerous developmental programs and cellular processes (Logan model system with which to study glutamatergic synapse formation and Nusse, 2004). In the nervous system of Drosophila,Wg and remodeling. Several proteins have been implicated in these signaling is involved in the formation of neuromuscular junctions processes, including components of canonical Wingless (Drosophila (NMJs) (Packard et al., 2002; Miech et al., 2008). Being a Wnt1) signaling and the giant isoforms of the membrane-cytoskeleton glutamatergic synapse, the Drosophila NMJ provides a useful linker Ankyrin 2, but possible interconnections and cooperation experimental model with which to study mammalian central between these proteins were unknown. Here, we demonstrate that nervous system synapses, their formation and remodeling (Collins the heterotrimeric G protein Go functions as a transducer of Wingless- and DiAntonio, 2007). The Drosophila NMJ is a beads-on-a-string- Frizzled 2 signaling in the synapse. We identify Ankyrin 2 as a target like structure that is formed at the axon terminus and is composed of – – of Go signaling required for NMJ formation. Moreover, the Go-ankyrin distinct circular structures the synaptic boutons which contain interaction is conserved in the mammalian neurite outgrowth pathway.
    [Show full text]
  • Circular RNA Hsa Circ 0005114‑Mir‑142‑3P/Mir‑590‑5P‑ Adenomatous
    ONCOLOGY LETTERS 21: 58, 2021 Circular RNA hsa_circ_0005114‑miR‑142‑3p/miR‑590‑5p‑ adenomatous polyposis coli protein axis as a potential target for treatment of glioma BO WEI1*, LE WANG2* and JINGWEI ZHAO1 1Department of Neurosurgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033; 2Department of Ophthalmology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130021, P.R. China Received September 12, 2019; Accepted October 22, 2020 DOI: 10.3892/ol.2020.12320 Abstract. Glioma is the most common type of brain tumor APC expression with a good overall survival rate. UALCAN and is associated with a high mortality rate. Despite recent analysis using TCGA data of glioblastoma multiforme and the advances in treatment options, the overall prognosis in patients GSE25632 and GSE103229 microarray datasets showed that with glioma remains poor. Studies have suggested that circular hsa‑miR‑142‑3p/hsa‑miR‑590‑5p was upregulated and APC (circ)RNAs serve important roles in the development and was downregulated. Thus, hsa‑miR‑142‑3p/hsa‑miR‑590‑5p‑ progression of glioma and may have potential as therapeutic APC‑related circ/ceRNA axes may be important in glioma, targets. However, the expression profiles of circRNAs and their and hsa_circ_0005114 interacted with both of these miRNAs. functions in glioma have rarely been studied. The present study Functional analysis showed that hsa_circ_0005114 was aimed to screen differentially expressed circRNAs (DECs) involved in insulin secretion, while APC was associated with between glioma and normal brain tissues using sequencing the Wnt signaling pathway. In conclusion, hsa_circ_0005114‑ data collected from the Gene Expression Omnibus database miR‑142‑3p/miR‑590‑5p‑APC ceRNA axes may be potential (GSE86202 and GSE92322 datasets) and explain their mecha‑ targets for the treatment of glioma.
    [Show full text]
  • Cardiomyopathy
    JACC: BASIC TO TRANSLATIONAL SCIENCE VOL.1,NO.5,2016 ª 2016 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN ISSN 2452-302X COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER http://dx.doi.org/10.1016/j.jacbts.2016.05.004 THE CC BY-NC-ND LICENSE (http://creativecommons.org/licenses/by-nc-nd/4.0/). PRE-CLINICAL RESEARCH FLNC Gene Splice Mutations Cause Dilated Cardiomyopathy a a b,c a d Rene L. Begay, BS, Charles A. Tharp, MD, August Martin, Sharon L. Graw, PHD, Gianfranco Sinagra, MD, e a a b,c,f b,c Daniela Miani, MD, Mary E. Sweet, BA, Dobromir B. Slavov, PHD, Neil Stafford, MD, Molly J. Zeller, b,c a d g g Rasha Alnefaie, Teisha J. Rowland, PHD, Francesca Brun, MD, Kenneth L. Jones, PHD, Katherine Gowan, a b,c a Luisa Mestroni, MD, Deborah M. Garrity, PHD, Matthew R.G. Taylor, MD, PHD VISUAL ABSTRACT HIGHLIGHTS Deoxyribonucleic acid obtained from 2 large DCM families was studied using whole-exome sequencing and cose- gregation analysis resulting in the iden- tification of a novel disease gene, FLNC. The2families,fromthesameItalian region, harbored the same FLNC splice- site mutation (FLNC c.7251D1G>A). A third U.S. family was then identified with a novel FLNC splice-site mutation (FLNC c.5669-1delG) that leads to haploinsufficiency as shown by the FLNC Western blot analysis of the heart muscle. The FLNC ortholog flncb morpholino was injected into zebrafish embryos, and when flncb was knocked down caused a cardiac dysfunction phenotype.
    [Show full text]
  • Next Generation Sequencing for Molecular Confirmation of Hereditary
    Arch Cardiol Mex. 2015;85(1):68---72 www.elsevier.com.mx SPECIAL ARTICLE Next generation sequencing for molecular confirmation of hereditary sudden cardiac death syndromes a,∗ b b b Manlio F. Márquez , David Cruz-Robles , Selene Ines-Real , Gilberto Vargas-Alarcón , a Manuel Cárdenas a Departamento de Electrofisiología, Instituto Nacional de Cardiología Ignacio Chávez, México, D.F., Mexico b Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, México, D.F., Mexico Received 26 March 2014; accepted 8 December 2014 KEYWORDS Abstract Hereditary sudden cardiac death syndromes comprise a wide range of diseases result- Arrhythmias; ing from alteration in cardiac ion channels. Genes involved in these syndromes represent diverse Hereditary sudden mutations that cause the altered encoding of the diverse proteins constituting these channels, cardiac death thus affecting directly the currents of the corresponding ions. In the present article we will syndromes; briefly review how to arrive to a clinical diagnosis and we will present the results of molecular Right ventricle genetic studies made in Mexican subjects attending the SCD Syndromes Clinic of the National arrhythmogenic Institute of Cardiology of Mexico City. cardiomyopathy; © 2014 Instituto Nacional de Cardiología Ignacio Chávez. Published by Masson Doyma México Brugada syndrome S.A. All rights reserved. PALABRAS CLAVE Confirmación diagnóstica molecular mediante secuenciación masiva de nueva Arritmias; generación (‘‘next generation sequencing’’) en síndromes hereditarios de muerte Síndromes súbita cardíaca hereditarios de Resumen Los síndromes hereditarios de muerte súbita cardíaca comprenden una amplia gama muerte súbita; Displasia de enfermedades resultantes de la alteración en los canales iónicos cardíacos. Los genes implicados en estos síndromes presentan mutaciones que causan alteraciones de las diversas Arritmogénica del proteínas que constituyen estos canales y que, por lo tanto, afectan directamente a las difer- ventriculo derecho; entes corrientes iónicas.
    [Show full text]
  • A Missense Mutation in the RSRSP Stretch of Rbm20 Causes Dilated
    www.nature.com/scientificreports OPEN A missense mutation in the RSRSP stretch of Rbm20 causes dilated cardiomyopathy and atrial fbrillation in mice Kensuke Ihara1,2*, Tetsuo Sasano2, Yuichi Hiraoka3, Marina Togo‑Ohno4, Yurie Soejima5, Motoji Sawabe5, Megumi Tsuchiya6, Hidesato Ogawa6, Tetsushi Furukawa1 & Hidehito Kuroyanagi4* Dilated cardiomyopathy (DCM) is a fatal heart disease characterized by left ventricular dilatation and cardiac dysfunction. Recent genetic studies on DCM have identifed causative mutations in over 60 genes, including RBM20, which encodes a regulator of heart‑specifc splicing. DCM patients with RBM20 mutations have been reported to present with more severe cardiac phenotypes, including impaired cardiac function, atrial fbrillation (AF), and ventricular arrhythmias leading to sudden cardiac death, compared to those with mutations in the other genes. An RSRSP stretch of RBM20, a hotspot of missense mutations found in patients with idiopathic DCM, functions as a crucial part of its nuclear localization signals. However, the relationship between mutations in the RSRSP stretch and cardiac phenotypes has never been assessed in an animal model. Here, we show that Rbm20 mutant mice harboring a missense mutation S637A in the RSRSP stretch, mimicking that in a DCM patient, demonstrated severe cardiac dysfunction and spontaneous AF and ventricular arrhythmias mimicking the clinical state in patients. In contrast, Rbm20 mutant mice with frame‑shifting deletion demonstrated less severe phenotypes, although loss of RBM20‑dependent alternative splicing was indistinguishable. RBM20S637A protein cannot be localized to the nuclear speckles, but accumulated in cytoplasmic, perinuclear granule‑like structures in cardiomyocytes, which might contribute to the more severe cardiac phenotypes. Dilated cardiomyopathy (DCM) is a fatal cardiac disease characterized by enlargement of the cardiac chambers and impaired systolic function1.
    [Show full text]
  • Blueprint Genetics Craniosynostosis Panel
    Craniosynostosis Panel Test code: MA2901 Is a 38 gene panel that includes assessment of non-coding variants. Is ideal for patients with craniosynostosis. About Craniosynostosis Craniosynostosis is defined as the premature fusion of one or more cranial sutures leading to secondary distortion of skull shape. It may result from a primary defect of ossification (primary craniosynostosis) or, more commonly, from a failure of brain growth (secondary craniosynostosis). Premature closure of the sutures (fibrous joints) causes the pressure inside of the head to increase and the skull or facial bones to change from a normal, symmetrical appearance resulting in skull deformities with a variable presentation. Craniosynostosis may occur in an isolated setting or as part of a syndrome with a variety of inheritance patterns and reccurrence risks. Craniosynostosis occurs in 1/2,200 live births. Availability 4 weeks Gene Set Description Genes in the Craniosynostosis Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ALPL Odontohypophosphatasia, Hypophosphatasia perinatal lethal, AD/AR 78 291 infantile, juvenile and adult forms ALX3 Frontonasal dysplasia type 1 AR 8 8 ALX4 Frontonasal dysplasia type 2, Parietal foramina AD/AR 15 24 BMP4 Microphthalmia, syndromic, Orofacial cleft AD 8 39 CDC45 Meier-Gorlin syndrome 7 AR 10 19 EDNRB Hirschsprung disease, ABCD syndrome, Waardenburg syndrome AD/AR 12 66 EFNB1 Craniofrontonasal dysplasia XL 28 116 ERF Craniosynostosis 4 AD 17 16 ESCO2 SC phocomelia syndrome, Roberts syndrome
    [Show full text]
  • Mackenzie's Mission Gene & Condition List
    Mackenzie’s Mission Gene & Condition List What conditions are being screened for in Mackenzie’s Mission? Genetic carrier screening offered through this research study has been carefully developed. It is focused on providing people with information about their chance of having children with a severe genetic condition occurring in childhood. The screening is designed to provide genetic information that is relevant and useful, and to minimise uncertain and unclear information. How the conditions and genes are selected The Mackenzie’s Mission reproductive genetic carrier screen currently includes approximately 1300 genes which are associated with about 750 conditions. The reason there are fewer conditions than genes is that some genetic conditions can be caused by changes in more than one gene. The gene list is reviewed regularly. To select the conditions and genes to be screened, a committee comprised of experts in genetics and screening was established including: clinical geneticists, genetic scientists, a genetic pathologist, genetic counsellors, an ethicist and a parent of a child with a genetic condition. The following criteria were developed and are used to select the genes to be included: • Screening the gene is technically possible using currently available technology • The gene is known to cause a genetic condition • The condition affects people in childhood • The condition has a serious impact on a person’s quality of life and/or is life-limiting o For many of the conditions there is no treatment or the treatment is very burdensome for the child and their family. For some conditions very early diagnosis and treatment can make a difference for the child.
    [Show full text]
  • Blueprint Genetics Comprehensive Growth Disorders / Skeletal
    Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel Test code: MA4301 Is a 374 gene panel that includes assessment of non-coding variants. This panel covers the majority of the genes listed in the Nosology 2015 (PMID: 26394607) and all genes in our Malformation category that cause growth retardation, short stature or skeletal dysplasia and is therefore a powerful diagnostic tool. It is ideal for patients suspected to have a syndromic or an isolated growth disorder or a skeletal dysplasia. About Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders This panel covers a broad spectrum of diseases associated with growth retardation, short stature or skeletal dysplasia. Many of these conditions have overlapping features which can make clinical diagnosis a challenge. Genetic diagnostics is therefore the most efficient way to subtype the diseases and enable individualized treatment and management decisions. Moreover, detection of causative mutations establishes the mode of inheritance in the family which is essential for informed genetic counseling. For additional information regarding the conditions tested on this panel, please refer to the National Organization for Rare Disorders and / or GeneReviews. Availability 4 weeks Gene Set Description Genes in the Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD ACAN# Spondyloepimetaphyseal dysplasia, aggrecan type, AD/AR 20 56 Spondyloepiphyseal dysplasia, Kimberley
    [Show full text]
  • Case Report Immunodeficiency in a Child with Rapadilino Syndrome: a Case Report and Review of the Literature
    CORE Metadata, citation and similar papers at core.ac.uk Provided by MUCC (Crossref) Hindawi Publishing Corporation Case Reports in Immunology Volume 2015, Article ID 137368, 4 pages http://dx.doi.org/10.1155/2015/137368 Case Report Immunodeficiency in a Child with Rapadilino Syndrome: A Case Report and Review of the Literature M. M. G. Vollebregt,1 A. Malfroot,1 M. De Raedemaecker,2 M. van der Burg,3 and J. E. van der Werff ten Bosch4 1 Department of Pediatrics, University Hospital Brussels, 1090 Brussels, Belgium 2DepartmentofGenetics,UniversityHospitalBrussels,1090Brussels,Belgium 3Department of Immunology, Erasmus MC, 3015 CN Rotterdam, Netherlands 4Department of Pediatric Hematology, Oncology and Immunology, University Hospital Brussels, 1090 Brussels, Belgium Correspondence should be addressed to J. E. van der Werff ten Bosch; [email protected] Received 3 February 2015; Accepted 31 March 2015 Academic Editor: Jiri Litzman Copyright © 2015 M. M. G. Vollebregt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Rapadilino syndrome is a genetic disease characterized by a characteristic clinical tableau. It is caused by mutations in RECQL4 gene. Immunodeficiency is not described as a classical feature of the disease. We present a 2-year-old girl with Rapadilino syndrome with important lymphadenopathies and pneumonia due to disseminated Mycobacterium lentiflavum infection. An immunological work-up showed several unexpected abnormalities. Repeated blood samples showed severe lymphopenia. Immunophenotyping showed low T, B, and NK cells. No Treg cells were seen. T cell responses to stimulations were insufficient.
    [Show full text]
  • Blueprint Genetics Comprehensive Skeletal Dysplasias and Disorders
    Comprehensive Skeletal Dysplasias and Disorders Panel Test code: MA3301 Is a 251 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of disorders involving the skeletal system. About Comprehensive Skeletal Dysplasias and Disorders This panel covers a broad spectrum of skeletal disorders including common and rare skeletal dysplasias (eg. achondroplasia, COL2A1 related dysplasias, diastrophic dysplasia, various types of spondylo-metaphyseal dysplasias), various ciliopathies with skeletal involvement (eg. short rib-polydactylies, asphyxiating thoracic dysplasia dysplasias and Ellis-van Creveld syndrome), various subtypes of osteogenesis imperfecta, campomelic dysplasia, slender bone dysplasias, dysplasias with multiple joint dislocations, chondrodysplasia punctata group of disorders, neonatal osteosclerotic dysplasias, osteopetrosis and related disorders, abnormal mineralization group of disorders (eg hypopohosphatasia), osteolysis group of disorders, disorders with disorganized development of skeletal components, overgrowth syndromes with skeletal involvement, craniosynostosis syndromes, dysostoses with predominant craniofacial involvement, dysostoses with predominant vertebral involvement, patellar dysostoses, brachydactylies, some disorders with limb hypoplasia-reduction defects, ectrodactyly with and without other manifestations, polydactyly-syndactyly-triphalangism group of disorders, and disorders with defects in joint formation and synostoses. Availability 4 weeks Gene Set Description
    [Show full text]
  • Craniosynostosis Precision Panel Overview Indications Clinical Utility
    Craniosynostosis Precision Panel Overview Craniosynostosis is defined as the premature fusion of one or more cranial sutures, often resulting in abnormal head shape. It is a developmental craniofacial anomaly resulting from a primary defect of ossification (primary craniosynostosis) or, more commonly, from a failure of brain growth (secondary craniosynostosis). As well, craniosynostosis can be simple when only one suture fuses prematurely or complex/compound when there is a premature fusion of multiple sutures. Complex craniosynostosis are usually associated with other body deformities. The main morbidity risk is the elevated intracranial pressure and subsequent brain damage. When left untreated, craniosynostosis can cause serious complications such as developmental delay, facial abnormality, sensory, respiratory and neurological dysfunction, eye anomalies and psychosocial disturbances. In approximately 85% of the cases, this disease is isolated and nonsyndromic. Syndromic craniosynostosis usually present with multiorgan complications. The Igenomix Craniosynostosis Precision Panel can be used to make a directed and accurate diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. Indications The Igenomix Craniosynostosis Precision Panel is indicated for those patients with a clinical diagnosis or suspicion with or without the following manifestations: ‐ Microcephaly ‐ Scaphocephaly (elongated head) ‐ Anterior plagiocephaly ‐ Brachycephaly ‐ Torticollis ‐ Frontal bossing Clinical Utility The clinical utility of this panel is: - The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient. - Early initiation of treatment in the form surgical procedures to relieve fused sutures, midface advancement, limited phase of orthodontic treatment and combined 1 orthodontics/orthognathic surgery treatment.
    [Show full text]